Risk of Failure to Achieve Revenue Due to Delays or Failures in Clinical Development
First written in FY2016. 13 of 14 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2022: 20 of 40 companies on the "Worse" side.
28 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「In particular, the development of pharmaceuticals can take more than 10 years from basic research to launch, and the Group has continued to incur operating losses and negative operating cash flow because research and development expenses are incurred ahead of revenue, among other factors.」
The Company continues to disclose the risk of operating losses and negative operating cash flow due to prolonged pharmaceutical development timelines and the front-loading of research and development expenses. - FY2023-Q3RestatedAnnual report
「In particular, the development of pharmaceuticals can take more than 10 years from basic research to launch, and the Group has continued to incur operating losses and negative operating cash flow because research and development expenses are incurred ahead of revenue, among other factors.」
The Company continues to disclose the risk of operating losses and negative operating cash flow due to prolonged pharmaceutical development timelines and the front-loading of research and development expenses. - FY2023-Q1RestatedAnnual report
「In particular, the development of pharmaceuticals can take more than 10 years from basic research to launch, and the Group has continued to incur operating losses and negative operating cash flow because research and development expenses are incurred ahead of revenue, among other factors.」
The Company continues to disclose the risk of operating losses and negative operating cash flow due to prolonged pharmaceutical development timelines and the front-loading of research and development expenses. - FY2022-Q3RestatedAnnual report
「In particular, the development of pharmaceuticals can take more than 10 years from basic research to launch, and the Group has continued to incur operating losses and negative operating cash flow because research and development expenses are incurred ahead of revenue, among other factors.」
The Company continues to disclose the risk of revenue shortfalls due to prolonged pharmaceutical development timelines and the front-loading of research and development expenses. - FY2022-Q1RestatedAnnual report
「In particular, the development of pharmaceuticals can take more than 10 years from basic research to launch, and the Group has continued to incur operating losses and negative operating cash flow because research and development expenses are incurred ahead of revenue, among other factors.」
The Company continues to disclose the risk of revenue shortfalls due to prolonged pharmaceutical development timelines and the front-loading of research and development expenses. - FY2021-Q3RestatedAnnual report
「The development of pharmaceuticals can take more than 10 years from basic research to launch, and the Group has continued to incur operating losses and negative operating cash flow because research and development expenses are incurred ahead of revenue, among other factors.」
The Company continues to disclose the risk of revenue shortfalls due to prolonged pharmaceutical development timelines and the front-loading of research and development expenses. - FY2021-Q2RestatedAnnual report
「In particular, the development of pharmaceuticals can take more than 10 years from basic research to launch, and the Group has continued to incur operating losses and negative operating cash flow because research and development expenses are incurred ahead of revenue, among other factors.」
The Company continues to disclose the risk of revenue shortfalls due to prolonged pharmaceutical development timelines and the front-loading of research and development expenses. - FY2021-Q1RestatedAnnual report
「The development of pharmaceuticals can take more than 10 years from basic research to launch, and the Group has continued to incur operating losses and negative operating cash flow because research and development expenses are incurred ahead of revenue, among other factors.」
The Company continues to disclose the risk of revenue shortfalls due to prolonged pharmaceutical development timelines and the front-loading of research and development expenses. - FY2020-Q3RestatedAnnual report
「In particular, the development of pharmaceuticals can take more than 10 years from basic research to launch, and the Group has continued to incur operating losses and negative operating cash flow because research and development expenses are incurred ahead of revenue, among other factors.」
The Company continues to disclose the risk of revenue shortfalls due to prolonged pharmaceutical development timelines and the front-loading of research and development expenses. - FY2020-Q2RestatedAnnual report
「The development of pharmaceuticals can take more than 10 years from basic research to launch, and the Group has continued to incur operating losses and negative operating cash flow because research and development expenses are incurred ahead of revenue, among other factors.」
The Company continues to disclose the risk of revenue shortfalls due to prolonged pharmaceutical development timelines and the front-loading of research and development expenses. - FY2020-Q1RestatedAnnual report
「The development of pharmaceuticals can take more than 10 years from basic research to launch, and the Group has continued to incur operating losses and negative operating cash flow because research and development expenses are incurred ahead of revenue, among other factors.」
The Company continues to disclose the risk of shortfalls in clinical development and revenue due to prolonged pharmaceutical development timelines and the front-loading of research and development expenses. - FY2018RestatedAnnual report
「However, there is no assurance that the Group's clinical development activities will proceed as planned, and progress may be delayed or the results of clinical development may fail to meet expectations.」
The Company continues to disclose the possibility that delays or failures in clinical development outcomes could delay or prevent the receipt of revenue and that research and development costs may not be recovered. - FY2017RestatedAnnual report
「There is no assurance that the Group's clinical development activities will proceed as planned, and progress may be delayed or the results of clinical development may fail to meet expectations.」
The Company continues to disclose the possibility that delays or failures in clinical development outcomes could delay or prevent the recognition of revenue from partners, and that in-house development costs may not be recovered. - FY2016First statedAnnual report
「There is no assurance that the Group's clinical development activities will proceed as planned, and progress may be delayed or the results of clinical development may fail to meet expectations.」
The Company explains the possibility that delays or failures in achieving events with partners could result in delays in or failure to receive revenue, and that in-house development costs may not be recovered.